Aurobindo Pharma Subsidiary Acquires Khandelwal’s Non-Oncology Business
Filing Summary
Aurobindo Pharma Limited’s wholly owned subsidiary, Auro Pharma Limited, has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited. The acquisition, executed through a Business Transfer Agreement, involves a cash consideration of INR 3,250 million. The business, which generated a turnover of INR 1,135 million in FY2024-25, includes 23 brands marketed in 67 SKUs and 9 pipeline products. The acquisition, effective January 1, 2026, aims to enhance Aurobindo’s domestic market presence in pain management and anti-infective segments.
Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Auro Pharma Limited, has approved the acquisition of the branded non-oncology prescription formulations business from Khandelwal Laboratories Private Limited. This acquisition is being conducted on a going concern basis through a Business Transfer Agreement. The transaction was approved at a meeting held on January 1, 2026.
The acquisition involves a cash consideration of INR 3,250 million, subject to adjustments for working capital as outlined in the definitive agreements. The business generated a turnover of INR 1,135 million in the fiscal year 2024-25, with an EBITDA of INR 289 million. The financial terms do not include any share acquisition or control over Khandelwal Laboratories, as the transaction is structured as a slump sale.
The acquired business comprises 23 brands marketed in 67 SKUs and 9 pipeline products, focusing primarily on anti-infective and pain management portfolios. The acquisition includes inventory, intellectual property, employees, and contracts. The business employs approximately 470 field force personnel and maintains a distribution network with over 1,600 stockists. This acquisition is expected to complement Aurobindo’s existing product portfolios in the domestic market.
The business has been operational since 1973-74 in the Indian pharmaceutical sector, focusing on branded non-oncology prescription formulations. The turnover for the last three fiscal years was reported as INR 1,049 million in 2022-23, INR 1,146 million in 2023-24, and INR 1,135 million in 2024-25. The acquisition does not require any governmental or regulatory approvals and is not classified as a related party transaction.
The transaction was signed and closed on January 1, 2026, marking the effective date of the acquisition. Auro Pharma Limited, incorporated under the Companies Act, 2013, is responsible for the acquisition. The company operates from its registered office in Hyderabad, Telangana.
Aurobindo Pharma Limited is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of active pharmaceutical ingredients and generic formulations. The company focuses on expanding its product offerings and strengthening its presence in the domestic and international markets through strategic acquisitions and partnerships.